PB Leiner's pharmaceutical portfolio expands

28-Oct-2022

The new variants have been specially designed to provide advanced solutions for reduced crosslinking and fast dissolution of soft caps

PB Leiner's pharmaceutical portfolio expands

PB Leiner has announced that its gelwoRx Dsolve pharmaceutical gelatin portfolio has been extended with three new products: Dsolve B, Dsolve P and Dsolve xTRA. 

Crosslinking is a natural phenomenon that causes a longer dissolution time of soft caps, a lower drug release rate and reduced stability and shelf life of the final dosage formulation. In order to provide a robust answer to crosslinking issues, the gelwoRx Dsolve product range has been extended with three new variants: Dsolve B, Dsolve P and Dsolve xTRA. 

The extended portfolio offers a variety of raw materials and dissolution performance. Dsolve P (pig skin) and Dsolve B (beef hide) have been specially designed to reduce crosslinking and show a better dissolution performance compared to the gold standard in soft caps gelatin. Meanwhile, Dsolve xTRA, a bovine bone gelatin innovation, boasts superior performance even when compared to Dsolve, Dsolve P and Dsolve B. 

Proven benefits 

Sign up for your free email newsletter

gelwoRx Dsolve significantly reduces crosslinking behaviour in the capsule’s shell. It promotes a faster dissolution of the capsules and guarantees a rapid filling release, improved stability, and increased shelf life of the final dosage formulations.